{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:33:53Z","timestamp":1768077233005,"version":"3.49.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To present the long-term (4-year) efficacy and safety of secukinumab in Taiwanese patients with active AS in the MEASURE 1 extension study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This <jats:italic>post hoc<\/jats:italic> analysis reports data from Taiwanese patients originally randomized to subcutaneous secukinumab 150 or 75mg or placebo every 4 weeks (following intravenous loading dose) who were invited to enter the 3-year extension study. Assessments at Week 208 included ASAS20\/40 responses and other clinically relevant endpoints. Efficacy data are presented as observed. Safety analyses included all patients who received \u22651 dose of secukinumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 57 Taiwanese patients in the core trial, 48 entered the extension study and 87.5% patients (42\/48) completed 4 years of treatment. Thirteen Taiwanese patients (including placebo-switchers) were escalated from 75 to 150mg (approved dose) at some point starting from Week 172. ASAS20\/40 responses were sustained through 4 years in the Taiwanese patients who were originally randomized to secukinumab 150mg. Clinical responses were improved in those patients who received dose-escalation from 75 to 150mg during the study. No unexpected safety signals were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secukinumab 150mg demonstrated sustained efficacy over 4 years in Taiwanese patients with active ankylosing spondylitis. The safety profile of secukinumab was consistent with previous reports.<\/jats:p><\/jats:sec><jats:sec><jats:title>ClinicalTrials.gov identifier<\/jats:title><jats:p>NCT01863732.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2020.561748","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T05:26:08Z","timestamp":1606368368000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1"],"prefix":"10.3389","volume":"11","author":[{"given":"Jui-Cheng","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"McCreddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Talloczy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1478-6354-13-S1-S4","article-title":"Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future","author":"Schett","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B4","article-title":"HLA-B27 and its subtypes in 4 Taiwanese Aborigine tribes: a comparison to Han Chinese patients with ankylosing spondylitis","volume":"30","author":"Chou","year":"2003","journal-title":"J Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200107000-00007","article-title":"Spondyloarthropathies in eastern Asia","volume":"13","author":"Feltkamp","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11926-013-0344-0","article-title":"Ankylosing spondylitis: Chinese perspective, clinical phenotypes, and associated extra-articular systemic features","volume":"15","author":"Ho","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00001","article-title":"Anti-IL17A in Axial Spondyloarthritis-Where Are We At","volume":"4","author":"Cheung","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/art.39416","article-title":"Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs","volume":"68","author":"Accortt","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.10.001","article-title":"Adverse effects of TNF inhibitors in SpA: are they different from RA","volume":"28","author":"Sampaio-Barros","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834640a9","article-title":"Similarities and differences between spondyloarthritis in Asia and other parts of the world","volume":"23","author":"Zhang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.13094","article-title":"Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies","volume":"20","author":"Wei","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.04.006","article-title":"Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis","volume":"21","author":"Jung","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01665.x","article-title":"Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient","volume":"28","author":"Montiel","year":"2008","journal-title":"Liver International: Off J Int Assoc Study Liver"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.12188","article-title":"Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia","volume":"17","author":"Navarra","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B19","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B22","article-title":"Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial [abstract]","volume":"70","author":"Baraliakos X","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.561748\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T05:26:10Z","timestamp":1606368370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.561748\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2020.561748"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.561748","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"article-number":"561748"}}